To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT05051865
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • camrelizumab — DRUG
    camrelizumab combined with SHR1020 for advanced melanoma
  • SHR1020 — DRUG
    camrelizumab combined with SHR1020 for advanced melanoma

Study Details

This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.

Key Dates

Start date
Oct 9, 2021
Status verified
Nov 2022
Primary completion
Aug 30, 2024
Completion
Aug 30, 2024

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab Combined With SHR1020
    Camrelizumab combined with SHR1020 for advanced melanoma.

Primary Outcome Measure

ORR (Objective Response Rate) [ Time Frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months ]

Central Contacts

Related Studies